Background: Heightened Stress has been shown to have acute adverse effects on cognitive function, and both stress and cognitive deficits have been found to be inversely associated with hippocampal volume reduction in both healthy and clinical samples. Further, heightened stress and cognitive deficits have been observed in individuals at clinical high risk (CHR) for psychosis in the North American Prodrome Longitudinal Study (NAPLS-2) as well as other studies of CHR groups. The present study utilizes data from NAPLS-2 to examine the relation of acute stress and hippocampal volume with cognitive performance in healthy youth and those at CHR for psychosis. Both the independent and additive relations of daily stress and hippocampal volume (HV) on cognition are examined. Methods: The sample was 666 participants (CHR=476; HC=190) who completed MRI scans, as well as measures of stress and cognitive function at the NAPLS-2 baseline assessment. The self-report stress measure was the Daily Stress Inventory (DSI) and cognitive performance was assessed with tests from the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) ). Hierarchical Linear regression analyses were conducted controlling for subject age, sex and intracranial volume (ICV) with test scores as the dependent measures and DSI scores and hippocampal volume as the predictors. Results: As expected, across subject groups, age was positively associated with performance on all of the cognitive measures, and females scored higher than males on the CPT-IP, WMS, and TMT. ICV was positively linked with performance on the TMT, WMS, NAB Mazes, CPT-IP, and BACS. For HC and CHR subjects combined, after entering covariates (sex, age and ICV), DSI, but not HV, was inversely associated with performance on the BVMT, HVLT, CPT-IP, and WMS. Neither DSI nor HV predicted performance on the NAB mazes or the BACS, beyond the variance accounted for by covariates. When analyses were conducted separately for the HC and CHR groups, DSI was not predictive of performance. Discussion: The present findings indicate that self-reported daily stress is inversely associated with cognitive performance on a variety of measures, and that this relation is not mediated by HV or any of the covariates in the combined sample of HC and CHR youth. Because the two groups differ in DSI scores, with CHR youth showing significantly higher stress scores, the combined samples represent a broader range of scores than either group alone. Thus, the within-group range of DSI scores is constrained and DSI is not predictive of performance within group. Instead, it appears that elevated stress is one factor contributing to cognitive deficits in CHR youth.
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Background: Larry Seidman, Ph.D. was a key contributor to the Consortium on the Genetics of Schizophrenia (COGS) with its focus on understanding the genetic substrates of quantitative endophenotypes in schizophrenia patients. With his deep knowledge of neurocognition related to psychosis, Larry was able to help steer the COGS-1 family study of over 300 families. The subsequent COGS-2 case-control study used the same well curated, quality controlled extensive battery of testing with 1411 schizophrenia patients and 1500 extensively tested healthy control subjects. Larry was first author on the 2015 paper "Factor structure and heritability of endophenotypes and schizophrenia: findings from the Consortium on the Genetics of Schizophrenia." It is important to note that related association studies examined the relationship of quantitative endophenotypes and genetic loci, and this is complementary to but distinct from case-control studies. These COGS studies identified a 42-gene network with a NRGL-ERBB4 hub underlying schizophrenia neurocognitive deficits. Thus, these Ns, modest for case-control studies, are quite powerful for gene finding using quantitative endophenotypic markers related to core "thought disorder" neurocognitive deficits in schizophrenia. These quantitative measures are up to 100 X more efficient and 10 X more powerful for gene finding than case-control studies as explained by Blangero, Williams and Almasy as early as 2005. Genes for SZ overlap with genes for key functionally important quantitative endophenotypes as shown by many groups, including COGENT and COGS, so case-control and endophenotype studies are best viewed as complementary in nature. Methods: Seidman et al (2015) examined 12 heritable neurocognitive and neurophysiological domains (including the Penn CNB Battery), as well as three neurophysiological measures reflecting inhibitory reprocessing from EEG and eye movements. Seidman et al's analysis revealed five distinct factors in the composite COGS battery. These were 1-episodic memory, 2-working memory, 3-perceptual vigilance, 4-visual abstraction and 5-inhibitory processing. The five factors had similar structures across probands, siblings and controls. Also, heritability was significant for all 5 factors. These composite endophenotype factors will be used to enhance our neurobiological and genetic understanding of schizophrenia and its treatment as we move forward, and are related to the Biotype concept of psychosis. Larry Seidman was also an important contributor to the COGS mission as described below. Results: The COGS PsychChip GWAS of quantitative endophenotypes has now identified six regions of association with quantitative neurocognitive measures exceeding genome-wide significance (e.g. NRGL3-Abstaction and Mental Flexibility on the CNB). In addition, many associations between endophenotypes and specific loci exceed the suggestive threshold for further investigation. Discussion: These data will be presented implicating synaptic plasticity and other crucial CNS processes in endophenotype dysfunction in SZ. NB: COGS interrogates the genetic architecture of endophenotypes associated with SZ and its functional outcome, not schizophrenia per se. Still, there is much overlap between risk genes for SZ and neurocognitive endophenotypes. Also neurocognitive endophenotypes are endorsed by the FDA and MATRICS as treatment targets for schizophrenia itself. This allows for data-guided drug and sensory-cognitive remediation of neurocognitive deficits to improve functional outcome in schizophrenia. Using this genomic information to enhance precision based selection of treatment options now seems to be an exciting and viable new treatment pathway.
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Background: Dr. Larry Seidman made numerous impactful contributions to our understanding of the roles of disrupted neurocognition and brain function in individuals with or at risk for schizophrenia. Based
